Introduction: Ibuprofen is a non-steroidal anti-inflammatory with anti-inflammatory, analgesic and antipyretic properties. The safety of ibuprofen was revised in 2006 and finally in 2015 it was confirmed that administration of high doses of ibuprofen is associated with an increased risk of arterial thrombosis.
Objectives: Testing the use of ibuprofen by users of the community pharmacy.
Material and methods: Data from this study descriptive, observational and cross-sectional are obtained from questionnaire of regular customers of the pharmacy in particular before signing a consent form and then being given advice through an information leaflet.
Results: 40 people were included exceeding the inclusion criteria, of which only one person had ibuprofen as chronic treatment. 82.5% used doses of 600 mg and 15.0% of 400 mg with a predominant dosage, every 8 hours, in both cases. 55.0% of people used ibuprofen until the pain subsided and uses were varied, being headache in first position.
Discussion: No one can corroborate what dose is most prevalent in other countries, but we can clarify that the dose of 600 mg is not marketed in some of them, such as France. This turns out to be the most used doses among the survey respondents exceeding the maximum dose of 1200 mg per day recommended by AEMPS to avoid a possible cardiovascular risk. Moreover, all ibuprofen indications that respondents used are correct, except of the cold that in Spain is not supported. Compared to other countries, we can see that this use is accepted in the United States and the United Kingdom by the relevant agencies of medication.